{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T21:06:59Z","timestamp":1787692019437,"version":"build-2784847793"},"reference-count":23,"publisher":"Oxford University Press (OUP)","funder":[{"name":"Takeda Pharmaceutical Company Limited"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn. J. Clin. Oncol."],"DOI":"10.1093\/jjco\/hyv149","type":"journal-article","created":{"date-parts":[[2015,10,21]],"date-time":"2015-10-21T20:51:42Z","timestamp":1445460702000},"page":"hyv149","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan"],"prefix":"10.1093","author":[{"given":"Kazuhiro","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikio","family":"Namiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyoshi","family":"Takabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentarou","family":"Kudou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Akaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,10,20]]},"reference":[{"issue":"(Suppl 5)","key":"2015102017584029000_hyv149v1.1","first-page":"187","article-title":"An international comparison of epidemiologic factors of prostate cancer","volume":"69","author":"Hinotsu","year":"2011","journal-title":"Nihon Rinsho"},{"key":"2015102017584029000_hyv149v1.2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyt038"},{"key":"2015102017584029000_hyv149v1.3","unstructured":"Cancer Information Service, National Cancer Center, Japan. Tokyo: Cancer statistics in Japan. http:\/\/ganjoho.jp\/public\/statistics\/pub\/statistics01.html (9 June 2015, date last accessed; in Japanese)."},{"key":"2015102017584029000_hyv149v1.4","unstructured":"Sobue T , Katanoda K , Ajiki W , Tsukuma H , Ioka A . White paper on cancer statistics in 2012. Tokyo: Shinoharashinsha Publishers Inc, 2012 (in Japanese)."},{"key":"2015102017584029000_hyv149v1.5","first-page":"9229","article-title":"Androgen receptor signaling in hepatocellular carcinoma and pancreatic cancers","volume":"20","author":"Kanda","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2015102017584029000_hyv149v1.6","unstructured":"The Japanese Urological Association. Practice guideline for prostate cancer in 2012. Tokyo: Kanehara & Co., Ltd, 2012 (in Japanese)."},{"key":"2015102017584029000_hyv149v1.7","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/CIA.S27931","article-title":"Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation","volume":"8","author":"Tunn","year":"2013","journal-title":"Clin Interv Aging"},{"key":"2015102017584029000_hyv149v1.8","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2011.50"},{"key":"2015102017584029000_hyv149v1.9","first-page":"587","article-title":"A phase II pharmacological study of leuprolide acetate 6-month depot, TAP-144-SR (6M), in treatment-naive patients with prostatic cancer who received a single subcutaneous or intramuscular injection","volume":"41","author":"Komura","year":"2014","journal-title":"Gan To Kagaku Ryoho"},{"key":"2015102017584029000_hyv149v1.10","first-page":"1343","article-title":"Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR","volume":"36","author":"Niijima","year":"1990","journal-title":"Hinyokika Kiyo"},{"key":"2015102017584029000_hyv149v1.11","first-page":"771","article-title":"Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients","volume":"48","author":"Koiso","year":"2002","journal-title":"Hinyokika Kiyo"},{"key":"2015102017584029000_hyv149v1.12","first-page":"781","article-title":"Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients","volume":"48","author":"Koiso","year":"2002","journal-title":"Hinyokika Kiyo"},{"key":"2015102017584029000_hyv149v1.13","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hys035"},{"key":"2015102017584029000_hyv149v1.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.08183.x"},{"key":"2015102017584029000_hyv149v1.15","unstructured":"Translational Research Informatics Center. Kobe: National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 2. 2014. http:\/\/202.70.140.4\/nccn\/guideline\/urological\/english\/prostate.pdf (9 June 2015, date last accessed)."},{"key":"2015102017584029000_hyv149v1.16","volume-title":"General Rule for Clinical and Pathological Studies on Prostate Cancer","author":"The Japanese Urological Association, The Japanese Society of Pathology, Japan Radiological Society","year":"2010"},{"key":"2015102017584029000_hyv149v1.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2015102017584029000_hyv149v1.18","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I"},{"key":"2015102017584029000_hyv149v1.19","unstructured":"National Cancer Institute. Maryland: Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (9 June 2015, date last accessed)."},{"key":"2015102017584029000_hyv149v1.20","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2008.52"},{"key":"2015102017584029000_hyv149v1.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.08.012"},{"key":"2015102017584029000_hyv149v1.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.11.041"},{"key":"2015102017584029000_hyv149v1.23","first-page":"690","article-title":"Sex differences in the evolution of the electrocardiographic QT interval with age","volume":"8","author":"Rautaharju","year":"1992","journal-title":"Can J Cardiol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/45\/12\/1168\/7195581\/hyv149.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T00:34:49Z","timestamp":1589589289000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article-lookup\/doi\/10.1093\/jjco\/hyv149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,20]]},"references-count":23,"alternative-id":["10.1093\/jjco\/hyv149"],"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyv149","relation":{},"ISSN":["0368-2811","1465-3621"],"issn-type":[{"value":"0368-2811","type":"print"},{"value":"1465-3621","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,20]]}}}